Oppenheimer Downgrades Alnylam Pharmaceuticals (ALNY) to Perform, "street expectations for ATTR-CM are optimistic in the face of two oral stabilizers expected to together constitute the standard-of-ca
Tweet Send to a Friend
(Updated - October 11, 2023 7:08 AM EDT)
Oppenheimer analyst Leland Gershell downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Leland Gershell downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
